The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...

8 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:NRIX) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below ...

About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, ...

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative ...